Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting. Methods:.A mul...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone
Format:	Artigo
Sprog:	Inglês
Udgivet:	Mattioli1885 2025-01-01
Serier:	Dermatology Practical & Conceptual
Fag:	efficacy cost per responder risankizumab secukinumab psoriasis
Online adgang:	https://dpcj.org/index.php/dpc/article/view/4838
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!